Tumor infiltrating CD19(+) B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors

The objective response rate (ORR) of tyrosine kinase inhibitors (TKIs) therapy in metastatic renal cell cancer (mRCC) patients was not satisfactory. Effective indicator of mRCC patient selection for TKI therapy is urgently needed. The function of tumor infiltrating B lymphocytes (TIBs) in tumor immu...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Lin, Zhiyuan, Liu, Li, Xia, Yu, Chen, Xiang, Xiong, Ying, Qu, Yang, Wang, Jiajun, Bai, Qi, Guo, Jianming, Xu, Jiejie
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6169591/
https://ncbi.nlm.nih.gov/pubmed/30288343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1477461
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados